World Economic Forum selects Intercell as "Technology Pioneer 2009"
Wien (euro adhoc) -
» The World Economic Forum (WEF) awards innovators of the highest
calibre, whose technologies have a deep impact on business and
society
» Intercell is the first Austrian company ever to be selected for this award
» Vaccine innovator Intercell's technologies, its clear product focus and the company's solid financial situation qualified Intercell as a Technology Pioneer
ots.CorporateNews transmitted by euro adhoc. The issuer is responsible for the content of this announcement.
innovations
Vienna (Austria), December 4, 2008 - Vaccine developer Intercell AG (VSE: ICLL) today announced that the World Economic Forum has selected Intercell as a Technology Pioneer 2009.
The WEF selected 34 visionary global companies for their accomplishments as innovators of the highest calibre, and whose technologies will have a deep impact on business and society. To be selected as a Technology Pioneer, a company must be involved in the development of life-changing technology innovation and have the potential for long-term impact on business and society. In addition, it must demonstrate visionary leadership and show all the signs of being a long-standing market leader - and its technology must be proven commercially.
"We are very honoured to be awarded the title of Technology Pioneer 2009," said Gerd Zettlmeissl, CEO Intercell AG. "Intercell has indeed applied a pioneering spirit to focus its strength in immunology and biotechnology for the development of novel vaccines for the benefit of people across the globe," added Gerd Zettlmeissl.
Intercell AG is the first company in Austria to be awarded the title of Technology Pioneer by the WEF since the program started 10 years ago. The entire list of Technology Pioneers, together with their profiles and interviews with the executives of the selected companies, can be found at: http://www.weforum.org/techpioneers.
end of announcement euro adhoc
Further inquiry note:
Intercell AG
Lucia Malfent
Head of Communications
Tel. +43 1 20620-1303
lmalfent@intercell.com
Branche: Biotechnology
ISIN: AT0000612601
WKN: A0D8HW
Index: ATX Prime, ATX
Börsen: Wiener Börse AG / official market